CLR 131 Induces Encouraging Responses in Relapsed/Refractory LPL and WM

A 100% objective response rate was observed with CLR 131 as treatment of patients with relapsed/refractory lymphoplasmacytic lymphoma and Waldenström’s macroglobulinemia in the ongoing phase 2 CLOVER-1 study.